 BOSTON, Nov. 05, 2020 GLOBE NEWSWIRE -- Aprea Therapeutics, Inc. Nasdaq: APRE, a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three and nine months ended September 30, 2020 and provided a business update. 